(Bloomberg Businessweek) -- For the past year the pandemic has brought a halt to in-person inspections of many pharmaceutical manufacturing facilities around the world. With a backlog of more than 1,000 audits to clear, the U.S. Food and Drug Administration is facing pressure to embrace something it’s long eschewed: virtual inspections of foreign drug plants.